CRISPR Therapy Pipeline: Every Approved and Trial Therapy
Interactive database of 60+ CRISPR therapies — targets, trial phases, efficacy data, and regulatory status.
Key Highlights
- ✓ 60+ CRISPR therapies cataloged
- ✓ Trial phase and efficacy data
- ✓ Editing strategies compared
- ✓ Regulatory milestone tracking
- ✓ Commercialization timeline predictions
Overview
A comprehensive guide to the CRISPR therapy landscape, covering every approved therapy and clinical trial. Includes target diseases, editing strategies, trial phases, efficacy data, and regulatory milestones.
What's Inside
Approved CRISPR Therapies
Casgevy (exa-cel) for sickle cell disease and beta-thalassemia became the first FDA-approved CRISPR therapy in late 2023. We examine the approval pathway, clinical trial results, pricing, and patient access programs.
Clinical Trial Landscape
60+ active trials spanning oncology, genetic diseases, cardiovascular, and infectious disease. We break down trials by phase, editing approach, delivery method, and target patient population.
Next-Generation Editing
Base editing and prime editing offer precision improvements over conventional CRISPR. We cover the clinical pipeline for these next-gen approaches, including Verve Therapeutics' base editing program for hypercholesterolemia.
Ready to dive in?
Explore this resource and discover more across our 12 technology frontiers.